Academia
The landscape may begin to become clearer as real-time research continues to emerge about the long-term effects of COVID-19 infection.
It’s something of the holy grail—run whole genome sequencing on a sample of a person’s blood and identify their risk for disease, all quickly and affordably. Oxford, England’s Genomics, founded in 2014 out of Oxford University by Sir Peter Donnelly, may be getting close.
There was a fair amount of clinical trial news last week. Here’s a look.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Researchers at the University of Birmingham have identified 14 small non-coding RNAs in saliva that can diagnose a concussion with 96% accuracy, based on sample analysis from 1,028 professional rugby players.
With the rise of mutant strains of SARS-CoV-2 and the unlikelihood of 100% compliance in getting vaccines out, investigators are focusing on developing even better vaccines and new drugs that might be able to knock back the disease. Here’s a look.
A new nonhuman primate Alzheimer’s disease model developed by researchers from University of California, Davis and elsewhere could open the door to getting better therapies into human testing.
The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.
A new report from University of Minnesota researchers shows that artificial heart valves implanted in lambs continued to grow and function for at least a year after surgery, a promising finding for pediatric patients in need of heart valve replacements.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
PRESS RELEASES